Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO Annual Meeting, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.

June 14, 2016

Results from the OCAT study, which evaluated whether intensification of adjuvant radiotherapy with concurrent chemotherapy or accelerated radiotherapy improves outcomes among patients with locally advanced, resectable, squamous cell carcinoma of the oral cavity.

Read more

June 13, 2016

A proprietary plasma DNA genomic sequencing platform demonstrated high sensitivity and positive predictive value, detected mutation sequences that confer resistance to therapy. Although regulatory, policy challenges remain, “next-generation” sequencing could have important clinical applications.

Read more

June 13, 2016

Drug development in oncology is providing much-needed new therapies to patients living with cancer, but there are important regulatory and economic issues that also must be addressed as they have an enormous influence on how, and where, drugs become available and who has access to those therapies.

Read more

June 10, 2016

Three KEYNOTE studies on pembrolizumab in metastatic melanoma provide insights into its long-term efficacy, its efficacy versus ipilimumab and its efficacy in combination with ipilimumab. What are the clues that hint at a cure for some patients with stage IV disease?

Read more

June 10, 2016

More than 2,000 patients are registered with the MBCP; 1,200 have consented to genetic sequencing. The MBCP has identified groups of traditionally underrepresented patients and patients with an ‘extraordinary response’ including more than 100 who have been living with mBC for more than 10 years.

Read more

June 10, 2016

The costs of cancer drugs can vary widely around the world and appear to rise unpredictably and irrespective of typical market forces from the time of their launch. Researchers explore the implications of drug cost and price, suggesting that who pays may be just as important as how much.

Read more

June 10, 2016

High-dose busulfan-melphalan followed by autologous stem cell rescue may be an effective treatment for highly selected patients with localized high-risk Ewing sarcoma but does not provide a significant efficacy benefit in patients with lung metastases, suggest results from two randomized trials.

Read more

June 10, 2016

Three abstracts detail data showing the role that evaluation of DNA damage repair genes have in tailoring treatment for metastatic prostate cancer and urothelial carcinoma.

Read more

June 9, 2016

Results from the phase III ETNA study concluded there was no statistical difference in the pCR rate between neoadjuvant nab-paclitaxel and paclitaxel both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Read more

June 8, 2016

Updated results from CheckMate 067 show that with a minimum of 18 months follow-up the combination of nivolumab plus ipilimumab is still significantly superior compared with ipilimumab alone for patient with advanced melanoma.

Read more

June 6, 2016

Treatment with binimetinib improved response rates and significantly prolonged progression-free survival compared with dacarbazine for patients with cutaneous melanoma with an NRAS mutation in the open-label, prospective phase III NEMO trial.

Read more

June 6, 2016

Pembrolizumab exhibited clinically significant antitumor activity against recurrent or metastatic head and neck squamous cell carcinoma in a phase II clinical trial. The drug was well tolerated in this heavily pretreated population, in which 84% of patients had two or more lines of previous therapy.

Read more

June 6, 2016

In a phase III trial, nivolumab demonstrated a “significant improval in survival” in patients with recurrent HNSCC, compared with therapy of the investigator’s choice. Nivolumab stabilized quality-of-life outcomes, while the investigator’s choice therapy led to declines in function.

Read more

June 6, 2016

Chemotherapy plays an important role in the treatment of soft tissue sarcoma across the disease spectrum, although acquisition of evidence supporting individual regimens has been hampered by small patient numbers, tumor heterogeneity, and differences in drug regimens, dosing, and therapy duration.

Read more

June 6, 2016

The Clinical Science Symposium on precision medicine detailed three large-scale efforts leveraging innovative trial designs and cutting-edge technology to break critical ground in the ability to pinpoint and utilize viable targeted therapies for individual patients. 

Read more

June 6, 2016

Though the field is in its infancy with regard to clinical data, there is increasing interest in combining checkpoint inhibitor therapy with surgery and/or radiotherapy in head and neck cancers. Experts discussed the state of the field at an Education Session on Monday.

Read more

June 6, 2016

Phase III trial CALGB 80802 failed to demonstrate OS benefit with addition of doxorubicin to sorafenib in the first-line treatment of advanced HCC. The results contradict earlier phase II data, and suggest that the role of chemotherapy in advanced HCC could come to an end.

Read more
June 6, 2016

The results of the phase II ECOG-ACRIN Cancer Research Group E2408 showed that adding bortezomib to induction bendamustine/rituximab improved the rate of complete response in patients with high-risk follicular lymphoma.

Read more

June 6, 2016

CRITICS reports on which adjuvant strategy, chemotherapy or chemoradiotherapy, provides better clinical outcomes for patients with resectable gastric cancer. What’s next for these patients? 

Read more

June 6, 2016

Results from the FAST study demonstrated that IMAB362, an antibody against claudin, a tight junction protein, significantly prolonged median PFS and OS in gastric cancers. 

Read more